The Benevolent Platform™ drives our three revenue streams. Our business model offers multiple routes for revenue generation and value creation.

End to End Drug Discovery.png

Drug discovery offerings

End to End Drug Discovery

  • Platform enables novel discoveries throughout the drug discovery process

  • Continuing to expand on our industry-leading collaborations

  • Validated by collaborations with Astrazeneca and Merck


Platform generated assets

Preclinical & Clinical Development Pipeline

  • 5 high potential assets

  • Potentially first-in-class or best-in-class assets providing novel therapeutic opportunities

  • Progressing assets to significant inflection points

Knowledge Exploration (1).png

New customisable SaaS products

Knowledge Exploration tools

  • Suite of AI products that surface data, perform analysis and give scientific recommendations

  • BenAI-Q and BenAI Research Assistant products enable enhance decisions making

  • Building from our core technologies to develop innovative ways to serve customers and their scientists


Reach your full research and development potential.

Speak to our business development team.

Contact us

Hear more about investment opportunities.

Speak to our investor relations team

Contact us